David Hutton

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

By co-culturing the differentiated microglia with retinal organoids, investigators found they may be able to recapitulate retinal development.

After 10 years, AREDS2 formula shows increased efficacy compared to original formula, benefit of eliminating beta-carotene.

With clearer imaging and enhanced resolution, the new OCT approach could improve medical diagnostic imaging.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

Biogen and Samsung Bioepis announce the launch of ranibizumab-nuna and detail when the ophthalmic biosimilar will be available for retina specialists.

A team of investigators has found that a comparison of ranibizumab and aflibercept showed both drugs safe and effective for treating diabetic macular edema.

According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular edema patients.

The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.

Outlook Therapeutics initially filed the BLA in March or the use of bevacizumab-vikg in the treatment of wet AMD. The company said it will re-submit a revised BLA by September.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DME.

According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

Retina Technologies Inc. is working on a modular digital vision screening platform it says will provide vision testing for the early detection of eye disorders.

In a patient survey, 66% of respondents said AI plays a large role in their diagnosis and treatment and thought it was important.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of DME.

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

According to the study, many patients with retinal vein occlusion maintain visual acuity gains above baseline at five years, but they require long-term monitoring and treatment.

Impact of native lipids on rhodopsin signaling and regeneration opens door to GPCR drug discovery in native membrane environments.

Researchers at the University of Southern California have stimulated the retinas of blind mice using focused ultrasound technology.

According to the company, post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints. The company plans to discuss findings with regulators in Q3.

The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.